Overview
ACAD market data
Price History
ACAD price chart
Valuation & Profitability
- P/E (TTM)
- 13.34 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $2.30 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.86 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 33.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $19.69 – $29.85 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $5.1B · P/B 3.68 · P/S 4.46.
Company News
Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41Benzinga · Aug 12, 2026, 10:05 AM
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39Benzinga · Aug 10, 2026, 3:11 PM
Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $25Benzinga · Aug 5, 2026, 5:14 PM
ACADIA Pharmaceuticals shares are trading higher after Citizens and RBC Capital raised their respective price targets on the stock.Benzinga · Aug 5, 2026, 4:49 PM
RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $37Benzinga · Aug 5, 2026, 3:21 PM
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36Benzinga · Aug 5, 2026, 2:56 PM
ACADIA Pharmaceuticals Raises FY2026 Sales Guidance from $1.220B-$1.280B to $1.240B-$1.300B vs $1.242B EstBenzinga · Aug 4, 2026, 8:33 PM
ACADIA Pharmaceuticals Q2 EPS $0.18 Beats $0.07 Estimate, Sales $307.959M Beat $295.857M EstimateBenzinga · Aug 4, 2026, 8:12 PM
BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $36Benzinga · Jul 21, 2026, 12:29 PM
Robinhood To Rally Around 24%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga · Jul 21, 2026, 11:51 AM